Galectin Therapeutics Inc. $GALT Shares Bought by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. raised its position in Galectin Therapeutics Inc. (NASDAQ:GALT) by 8.8% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 423,235 shares of the company’s stock after purchasing an additional 34,300 shares during the period. Geneos Wealth Management Inc. owned about 0.67% of Galectin Therapeutics worth $516,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Galectin Therapeutics during the first quarter valued at $34,000. Bank of America Corp DE boosted its stake in shares of Galectin Therapeutics by 101.4% during the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after acquiring an additional 19,316 shares during the last quarter. Vivaldi Capital Management LP boosted its stake in shares of Galectin Therapeutics by 89.9% during the fourth quarter. Vivaldi Capital Management LP now owns 45,628 shares of the company’s stock valued at $56,000 after acquiring an additional 21,596 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Galectin Therapeutics by 46.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,510 shares of the company’s stock valued at $66,000 after acquiring an additional 16,412 shares during the last quarter. Finally, HighTower Advisors LLC boosted its stake in shares of Galectin Therapeutics by 244.1% during the first quarter. HighTower Advisors LLC now owns 77,375 shares of the company’s stock valued at $94,000 after acquiring an additional 54,889 shares during the last quarter. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Price Performance

NASDAQ GALT opened at $5.37 on Monday. The firm has a market capitalization of $344.00 million, a P/E ratio of -8.39 and a beta of 0.86. Galectin Therapeutics Inc. has a 1-year low of $0.73 and a 1-year high of $6.55. The business’s 50-day simple moving average is $3.67 and its 200-day simple moving average is $2.30.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.04. On average, equities research analysts expect that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wall Street Zen raised Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 21st. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Galectin Therapeutics in a research note on Thursday, August 14th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $6.00.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.